Business
First-In-Human Study In The Bag, Glucotrack Gears Up For Long-Term Trial Of Potentially Groundbreaking Continuous Blood Glucose Monitor For Diabetes Patients
By JE Insights, Benzinga DETROIT, MICHIGAN - May 14, 2025 (NEWMEDIAWIRE) - Among the more challenging chronic conditions, diabetes represents both a social
About this update from Glucotrack, Inc.
[{"type":"text","content":"By JE Insights, Benzinga\nDETROIT, MICHIGAN - May 14, 2025 (NEWMEDIAWIRE) - Among the more challenging chronic conditions, diabetes represents both a social and economic burden, particularly for insulin-dependent cases. According to the National Diabetes Statistics Report, 38.4 million people of all ages - or 11.6% of the U.S. population - had diabetes. Of this, 1.7 million adults aged 20 years or older - or 5.7% of all U.S. adults with diagnosed diabetes - reported having the type 1 variant and using insulin. \n An autoimmune disease, type 1 diabetes impacts the body's ability to produce insulin - the hormone the body uses to allow sugar or glucose to enter cells to produce energy - leaving the pancreas with the ability to produce only a little or no insulin at all. What makes this variant particularly vexing is that complications can affect major organs, including the heart, blood vessels, nerves, eyes and kidneys. Subsequently, normalizing blood sugar levels can lower the risk of many complications.\nThe CDC also reported that about 90% to 95% of the U.S. diabetic population has advanced or type 2 diabetes. If you have type 2 diabetes, cells don't respond normally to insulin. This is called insulin resistance, and many of the complications and risks are the same for both types of diabetes.\nTo manage these risks, patients with insulin-dependent diabetes - both type 1 and advanced type 2 - must monitor their glucose levels. However, traditional methodologies such as continuous glucose monitors (CGMs) suffer from the following pain points and challenges:\n Traditional CGMs measure interstitial fluid, not blood, thereby potentially introducing delays, especially during rapid glucose swings when interstitial glucose levels may lag blood glucose levels.\n\n On-body wearables - such as external patches and transmitters - are visible, cumbersome and can irritate the skin or fall off prematurely.\n\n Most CGMs require frequent sensor replacements (often within seven to 15 days), so managing supplies can be a hassle.\n\n \n Fundamentally, it is these challenges that Glucotrack Inc. (NASDAQ: GCTK) seeks to address through a radical departure from traditional diabetes management with its intravascular Continuous Blood Glucose Monitor (CBGM). By measuring directly from the blood, the CBGM enables real-time readings, which the company say...